References

1. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol 2003; 21:1263-1270.

2. Horning SJ. Future directions in radioimmunotherapy for B-cell lymphoma. Semin Oncol 2003; 30(suppl):29-34.

3. Press OW. Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective. Semin Oncol 2003; (suppl):10-21.

4. Press OW, Unger JM, Braziel RM, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003; 102:1606-1612.

5. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352:441 -449.

6. O'Donoghue, J.A. The implications of non-uniform tumor doses for radioimmunotherapy. J Nucl Med 1999; 40:1337-1341.

7. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. Nature 2004; 427:695.

8. Goldenberg DM, DeLand F, Kim E, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978; 298: 1384 - 1386.

9. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-497.

10. Divgi CR, Scott AM, Dantis L, et al. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J Nucl Med 1995; 36:586-592.

11. Billetta R, Lobuglio AF. Chimeric antibodies. Int Rev Immunol 1993; 10:165-176.

12. Caron PC, Schwartz MA, Co MS, et al. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia. Cancer 1994; 73(suppl):1049-1056.

13. Delaloye B, Bischof-Delaloye A, Buchegger F, et al. Detection of colorec-tal carcinoma by emission-computerized tomography after injection of 123I-labeled Fab or F(ab')2 fragments from monoclonal anti-carcinoem-bryonic antigen antibodies. J Clin Invest 1986; 77:301-311.

14. Chang CN, Landolfi NF, Queen C. Expression of antibody Fab domains on bacteriophage surfaces. Potential use for antibody selection. J Immunol 1991; 147:3610-3614.

15. Zaccolo M, Griffiths AP, Prospero TD, Winter G, Gherardi E. Dimerization of Fab fragments enables ready screening of phage antibodies that affect hepatocyte growth factor/scatter factor activity on target cells. Eur J Immunol 1997; 27:618-623.

16. Webber KO, Reiter Y, Brinkmann U, Kreitman R, Pastan I. Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog. Mol Immunol 1995; 32:249-258.

17. Tuttle WK III, Brown PH. Applying Nuclear Regulatory Commission guidelines to the release of patients treated with sodium iodine-131. J Nucl Med Technol 2000; 28:275-279.

18. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329:1219-1224.

19. Carrasquillo JA, Mulshine JL, Bunn PA Jr., et al. Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. J Nucl Med 1987; 28:281-287.

20. Garg PK, Alston KL, Welsh PC, Zalutsky MR. Enhanced binding and inertness to dehalogenation of alpha-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate. Bioconjug Chem 1996; 7:233-239.

21. Wiseman GA, Witzig TE. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma. Cancer Biother Radio-pharm 2005; 20:185-188.

22. Smith-Jones PM. Radioimmunotherapy of prostate cancer. Q J Nucl Med Mol Imaging 2004; 48:297-304.

23. Guhlke S, Beets AL, Oetjen K, Mirzadeh S, Biersack HJ, Knapp FF Jr. Simple new method for effective concentration of 188Re solutions from alumina-based 188W-188Re generator. J Nucl Med 2000; 41:1271-1278.

24. Postema EJ, Boijesson PK, Buijs WC, et al. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer. J Nucl Med 2003; 44(10):1690-1699.

25. Zalutsky M, Reardon D, Akabani G, et al. Astatine-211 labeled human/ mouse chimeric anti-tenascin monoclonal antibody via surgically created resection cavities for patients with recurrent gliomas: phase I study. Neu-rooncology 2002; 4:S103 (Abstr).

26. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002; 100:1233-1239.

27. Miederer M, McDevitt MR, Sgouros G, Kramer K, Cheung NK, Scheinberg DA. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med 2004; 45:129-137.

28. Adelstein SJ, Kassis AI, Bodei L, Mariani G. Radiotoxicity of iodine-125 and other auger-electron-emitting radionuclides: background to therapy. Cancer Biother Radiopharm 2003; 18:301-316.

29. Behr TM, Sharkey RM, Juweid ME, et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med 1997; 38:858-870.

30. Juweid ME, Sharkey RM, Behr T, et al. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2. J Nucl Med 1996; 37:1504-1510.

31. Juweid M, Sharkey RM, Behr TM, et al. Clinical evaluation of tumor targeting with the anticarcinoembryonic antigen murine monoclonal antibody fragment, MN-14 F(ab)2. Cancer 1996; 78:157-168.

32. Behr TM, Liersch T, Greiner-Bechert L, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 2002; 94(suppl):1373 - 81.

33. Hajjar G, Sharkey RM, Burton J, et al. Phase I radioimmunotherapy trial with iodine-131-labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer 2002; 2:31-42.

34. Wong JY, Chu DZ, Yamauchi D, et al. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients. J Nucl Med 1998; 39:2097-2104.

35. Wong JYC, Chu DZ, Yamauchi DM, et al. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res 2000; 6:3855-3863.

36. Koppe MJ, Soede AC, Pels W, et al. Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin. Int J Cancer 2003 Oct 10; 106(6): 965-972.

37. Winter G. Synthetic human antibodies and a strategy for protein engineering. FEBS Lett 1998; 430:92-94. Review.

38. Begent RH, Ledermann JA, Green AJ, et al. Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorec-tal cancer. Br J Cancer 1989; 60:406-412.

39. Begent RH, Verhaar MJ, Chester KA, et al. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 1996; 2:979-984.

40. Molinolo A, Simpson JF, Thor A, Schlom J. Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res 1990; 50:1291-1298.

41. Divgi CR, Scott AM, McDermott K, et al. Clinical comparison of radiolo-calization of two monoclonal antibodies (mAbs) against the TAG-72 antigen. Nucl Med Biol 1994; 21:9-15.

42. Murray JL, Macey DJ, Kasi LP, et al. Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer. Cancer 1994; 73(suppl): 1057-1066.

43. Divgi CR, Scott AM, Gulec S, et al. Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxysper-gualin in metastatic colon carcinoma. Clin Cancer Res 1995; 1: 1503-1510.

44. Rogers BE, Roberson PL, Shen S, et al. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region. Cancer Biother Radiopharm 2005; 20:502-13.

45. Macey DJ, Grant EJ, Kasi L, et al. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial. Clin Cancer Res 1997; 3:1547-1555.

46. Meredith RF, Khazaeli MB, Macey DJ, et al. Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin Cancer Res 1999; 5(suppl):3254s-3258s.

47. Meredith RF, Khazaeli MB, Plott WE, et al. Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with meta-static colorectal cancer. Clin Cancer Res 1996; 2:1811-1818.

48. Mulligan T, Carrasquillo JA, Chung Y, et al. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res 1995; 1:1447-1454.

49. Alvarez RD, Partridge EE, Khazaeli MB, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol 1997; 65:94-101.

50. Meredith RF, Alvarez RD, Partridge EE, et al. Intraperitoneal radioimmu-nochemotherapy of ovarian cancer: a phase I study. Cancer Biother Radio-pharm 2001; 16:305-315.

51. Alvarez RD, Huh WK, Khazaeli MB, et al. A phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 2002; 8:2806-2811.

52. Colcher D, Bird R, Roselli M, et al. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 1990; 82:1191-1197.

53. Milenic DE, Yokota T, Filpula DR, et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pan carcinoma monoclonal antibody CC49. Cancer Res 1991; 51:6363-6371.

54. Adams GP, McCartney JE, Tai MS, et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 1993; 53:4026-4034.

55. Yokota T, Milenic DE, Whitlow M, Wood JF, Hubert SL, Schlom J. Micro autoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res 1993; 53:3776-3783.

56. Larson SM, El-Shirbiny AM, Divgi CR, et al. Single chain antigen binding protein (scFv CC49): first human studies in colorectal carcinoma metastatic to liver. Cancer 1997; 80:2458-2468.

57. Welt S, Divgi CR, Kemeny N, et al. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1994; 12:1561-1571.

58. Daghighian F, Barendswaard E, Welt S, et al. Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody. J Nucl Med 1996; 37:1052-1057.

59. Welt S, Scott AM, Divgi CR, et al. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1996; 14:1787-1797.

60. Barendswaard EC, Scott AM, Divgi CR, et al. Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice. Int J Oncol 1998; 12:45-53.

61. Meredith RF, Khazaeli MB, Plott WE, et al. Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. J Nucl Med 1995; 36:2229-2233.

62. Welt S, Divgi CR, Scott AM, et al. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol 1994; 12:1193-1203.

63. Scott AM, Wiseman G, Welt S, et al. A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibro-blast activation protein-positive cancer. Clin Cancer Res 2003; 9:1639-1647.

64. Rubin SC, Kostakoglu L, Divgi C, et al. Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX35 in patients with epithelial ovarian cancer. Gynecol Oncol 1993; 51:61-66.

65. Finstad CL, Lloyd KO, Federici MG, et al. Distribution of radiolabeled monoclonal antibody MX35 F(ab')2 in tissue samples by storage phosphor screen image analysis: evaluation of antibody localization to micrometastatic disease in epithelial ovarian cancer Clin Cancer Res 1997; 8:1433-1442.

66. van Zanten-Przybysz I, Molthoff CF, Roos JC, et al. Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. J Nucl Med 2000; 41:1168-1176.

67. Nicholson S, Gooden CS, Hird V, et al. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis. Oncol Rep 1998; 5:223-226.

68. DeNardo SJ, Kramer EL, O'Donnell RT, et al. Radioimmunotherapy for breast cancer using indium-111 /yttrium-90 BrE-3: results of a phase I clinical trial. J Nucl Med 1997; 38:1180-1185.

69. Kramer EL, Liebes L, Wasserheit C, et al. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer. Clin Cancer Res 1998; 4:1679-1688.

70. Richardson RB, Kemshead JT, Davies AG, et al. Dosimetry of intrathecal iodine131 monoclonal antibody in cases of neoplastic meningitis. Eur J Nucl Med 1990; 17:42-48.

71. Moseley RP, Davies AG, Richardson RB, et al. Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. Br J Cancer 1990; 62:637-642.

72. Hopkins K, Kemshead JT. Progress review: intrathecal and intratumoral injection of radiolabeled monoclonal antibodies (MoAbs) for the treatment of central nervous system(CNS) malignancies. J Drug Target 1993; 1:175-183.

73. Bigner DD, Brown M, Coleman RE, et al. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2—a preliminary report. J Neurooncol 1995; 24:109-122.

74. Papanastassiou V, Pizer BL, Chandler CL, Zananiri TF, Kemshead JT, Hopkins KI. Pharmacokinetics and dose estimates following intrathecal administration of 131I-monoclonal antibodies for the treatment of central nervous system malignancies. Int J Radiat Oncol Biol Phys 1995; 31:541-552.

75. Kemshead JT, Hopkins KI, Chandler CL. Treatment of diffuse leptomenin-geal malignancy by intrathecal injection of 131I radioimmunoconjugates. Recent Results. Cancer Res 1996; 141:145-158.

76. Brown MT, Coleman RE, Friedman AH, et al. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with lepto-meningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res 1996;2:963-972.

77. Kramer K, Cheung NK, Humm JL, et al. Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8. Med Pediatr Oncol 2000; 35:716-718.

78. Zalutsky MR, Stabin MG, Larsen RH, Bigner DD. Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate. Nucl Med Biol 1997; 24: 255-261.

79. Saleh MN, Sugarman S, Murray J, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol 2000; 18:2282-2292.

80. Pai-Scherf LH, Carrasquillo JA, Paik C, et al. Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY B3. Clin Cancer Res 2000; 6: 1720-1730.

81. Kitamura K, Stockert E, Garin-Chesa P, et al. Specificity analysis of blood group Lewis-y (Le(y)) antibodies generated against synthetic and natural Le(y) determinants. Proc Natl Acad Sci 1994; 91:12957-12961.

82. Oosterwijk E, Bander NH, Divgi CR, et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 1993; 11:738-750.

83. Divgi CR, Bander NH, Scott AM, et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998; 4:2729-2739.

84. Steffens MG, Boerman OC, de Mulder PH, et al. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999; 5:3268s-3274s.

85. Divgi CR, O'Donoghue JA, Welt S, et al. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 2004 Aug; 45(8):1412-1421.

86. O'Donoghue JA, Sgouros G, Divgi CR, Humm JL. Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry. J Nucl Med 2000; 41:538-547.

87. Meredith RF, Bueschen AJ, Khazaeli MB, et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 1994; 35:1017-1022.

88. Slovin SF, Scher HI, Divgi CR, et al. Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clin Cancer Res 1998; 4:643-651.

89. Nanus DM, Milowsky MI, Kostakoglu L, et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 2003; 170:S84-S88.

90. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005; 23:4591-4601.

91. Vallabhajosula S, Goldsmith SJ, Hamacher KA, et al. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunother-apy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med 2005; 46:850-858.

92. Breitz HB, Weiden PL, Beaumier PL, et al. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-D0TA-biotin. J Nucl Med 2000; 41:131-140.

93. Breitz H, Knox S, Widen P, et al. Pretargeted radioimmunotherapy with antibody-streptavidin and Y-90 DOTA-biotin (Avicidin): result of a dose escalation study. J Nucl Med 1998; 39:71P.

94. Paganelli G, Bartolomei M, Ferrari M, et al. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 2001; 16:227-235.

95. Sharkey RM, McBride WJ, Karacay H, et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res 2003; 63:354-363.

96. Bardies M, Bardet S, Faivre-Chauvet A, et al. Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. J Nucl Med 1996; 37:1853-1859.

97. Rosch F, Herzog H, Plag C, et al. Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography. Eur J Nucl Med 1996; 23:958-966.

98. Jamar F, Barone R, Mathieu I, et al. 86Y-D0TA0)-D-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003; 30:510-518.

99. Goodwin DA, Meares CF. Advances in pretargeting biotechnology. Biotechnol Adv 2001; 19:435-450.

100. Yoo TM, Chang HK, Choi CW, et al. Technetium-99 m labeling and biodistribution of anti-TAC disulfide-stabilized Fv fragment. J Nucl Med 1997; 38:294-300.

101. Wu AM. Engineering multivalent antibody fragments for in vivo targeting. Methods Mol Biol 2004; 248:209-225.

102. Bauer S, Adrian N, Williamson B, et al. Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein. J Immunol 2004; 172:3930-3939.

103. DeNardo GL, Schlom J, Buchsbaum DJ, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 2002; 94(4 suppl): 1332-1348.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment